Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights - Episode 6
ASH 2024 Updates: EPCORE NHL-2 Trial With Fixed-Duration Epcoritamab + R2
Panelists discuss the 2-year follow-up data from the EPCORE NHL-2 trial with fixed-duration epcoritamab + lenalidomide and rituximab (R2) presented at the American Society of Hematology (ASH), and how the potential move of epcoritamab from the third-line (3L) to the second-line (2L) setting might impact treatment approaches.
Video content above is prompted by the following:
Another update at ASH this year was the 2-year follow-up from the EPCORE NHL-2 trial with fixed-duration epcoritamab + R2. what were your thoughts on these data, and how do you anticipate this will impact your treatment approach if epcoritamab moves from the 3L to the 2L setting?